Retatrutide is an investigational once-weekly triple agonist that targets GLP-1, GIP, and glucagon receptors
The compound reaches skin, hair follicles, internal organs, joints, and the nervous system
Unlike GSH, N-acetylcysteine NAC crosses the blood-brain barrier and might be expected to influence systemic and cerebral GSH levels
The most frequently reported clinical outcomes included initial hospitalization or prolonged hospitalization (13.6%) and other serious medical events (12.3%)
But abandoning the target dose prematurely means the patient never gets the full benefit they were prescribed the medication to achieve." Document the Decision If a patient and prescriber jointly decide to maintain a sub-target dose, document the rationale, the expected reduction in efficacy, and the plan for reassessment